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Background: The goal of this pilot study was to design an external quality assessment (EQA) scheme for German cystic fibrosis (CF)
clinical microbiology laboratories. Therefore, a multicentre study of 18 German CF laboratories was performed to evaluate their proficiency
in analyzing CF respiratory secretions.
Methods: Simulated clinical specimens containing a set of four frequent CF pathogens, namely two Pseudomonas aeruginosa strains
differing in morphotype (mucoid versus non-mucoid) and resistotype, one Staphylococcus aureus strain and one Burkholderia multivorans
strain, were distributed to each laboratory. Isolation, identification and antimicrobial susceptibility testing (AST) of any bacterial pathogen
present and completion of a questionnaire about applied microbiological protocols were requested.
Results: Three of four strains were isolated and identified correctly by almost all laboratories. B. multivorans was once misidentified as
Burkholderia cenocepacia. Fourteen laboratories failed to detect the second multidrug resistant P. aeruginosa isolate. AST errors occurred
most often for P. aeruginosa 2 followed by B. multivorans, P. aeruginosa 1 and S. aureus. Evaluation of the questionnaires revealed major
differences in cultivation and identification techniques applied by the participating laboratories.
Conclusions: A periodical EQA programme for German CF laboratories and standardized microbiological procedures seem to be necessary
to advance diagnostic microbiology employed on CF respiratory tract specimens and may help to improve anti-infective treatment and
infection control practices for CF patients.
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Cystic fibrosis (CF) is the most common hereditary
disease in the Caucasian population and results from
mutations in the CF transmembrane conductance regulator
(CFTR) gene. The CFTR defect leads to an imbalance in the⁎ Corresponding author. Marchioninistr, 17, D-81337München, Germany.
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doi:10.1016/j.jcf.2007.02.007epithelial electrolyte transport and multiple organ dysfunc-
tions. In the CF lung, copious amounts of viscous respiratory
secretions and impaired airway clearance cause recurrent
bacterial infections with intense inflammation, airway
obstruction, progressive lung tissue destruction and ulti-
mately respiratory failure [1,2].
CF lung infection typically begins with the acquisition of
Staphylococcus aureus and Haemophilus influenzae, fol-
lowed by chronic Pseudomonas aeruginosa pneumonia, that
remains the major cause of morbidity and mortality among
CF patients [3,4]. In addition, Burkholderia cepacia
complex, Stenotrophomonas maltophilia, Achromobactered by Elsevier B.V. All rights reserved.
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pathogens like Pandoraea spp. and Inquilinus limosus
further aggravate pulmonary infection in CF patients [5–9].
As a consequence of this progressive microbiological
history periodical microbiological examinations of CF
respiratory secretions remain cornerstones in the clinical
management of CF lung disease [10–12].
Thus, accurate microbiological diagnostic employed on CF
respiratory secretions is critical to ensure appropriate anti-
microbial treatment and the implementation of reliable hygienic
measures like segregation of patients with a respiratory tract
culture that is positive forP. aeruginosa orB. cepacia complex.
During chronic stages of CF pneumonia microbiological
examinations are complicated by the fact that respiratory
samples obtained from CF patients often contain a mixture of
different species and/or high quantities of diverse morpho-
types and resistotypes, such as mucoid and non-mucoid
P. aeruginosa, biochemical inactive, small colony, hypermu-
table andmultidrug resistant (MDR) variants of pathogens that
persisted for years [3,13,14]. Cultures performed on CF
specimens commonly involve the use of many medium types,
in particular selective media that facilitate the recovery of
potential pathogens such as S. aureus, P. aeruginosa and
B. cepacia complex from the complexmicroflora of CF airway
secretions [15–19]. Therefore, the microbiological diagnosis
of CF respiratory tract infections is labor-intensive and im-
plies a wide experience in the field of CF microbiology.
About 8000 patients suffering from CF live in the Federal
Republic of Germany and most of them are followed at about
120 different CF centres. In agreement, respiratory secretions
of CF patients are analyzed in several microbiological
laboratories all over Germany and on request by two consiliary
laboratories on CF microbiology appointed by the Robert
Koch Institute (in Munich: Consiliary Laboratory South,
CLSth and in Hanover: Consiliary Laboratory North, CLNth).
To assess and continuously improve the quality of the
microbiological laboratory performance in Germany, nation-
al external quality assessment (EQA) schemes are generally
conducted for all kinds of routine microbiological proce-
dures based on quality standards in microbiology-infectio-
logic diagnostics, denoted as MiQ and issued by the German
Society for Hygiene and Microbiology (DGHM). EQA trials
are organized and performed by the INSTAND organization
(Institute for Standardization and Documentation in Medical
Laboratories) on behalf of the Board of the Federal Medical
Council. However, during this study neither specific recom-
mendations for clinical microbiology protocols, as available
from American authorities, nor EQA schemes for CF
respiratory tract samples existed in Germany [20,21].
In summary, the reliable microbiological diagnosis of CF
lung infections imposes a particular challenge for clinical
microbiology laboratories due to (i) the unique spectrum of
typical CF pathogens and a variety of rarely occurring
unusual non-fermentative bacteria, (ii) the broad phenotypic
diversity of CF isolates descending from one initial infecting
clone and (iii) the increasing selection of MDR variants. Theaim of this study was to design an EQA scheme for German
microbiological laboratories regularly processing CF respi-
ratory tract specimens. Therefore, a multilaboratory trial was
organized by preparing simulated CF specimens that were
sent by mail to 18 CF microbiological laboratories. The
proficiency of participants was assessed regarding isolation,
identification and antimicrobial susceptibility testing (AST)
of classical CF pathogens. Moreover, they were asked to
complete a questionnaire about applied “in-house” labora-
tory protocols.
In conclusion, the results of this study revealed important
reporting errors in terms of CF test specimens and relevant
differences in routine laboratory procedures and argue for the
implementation of a continuous German EQA programme
based on harmonized methodologies to improve the micro-
biological diagnosis of respiratory samples from CF patients.
2. Materials and methods
2.1. Bacterial strains and test specimens
Two identical freeze-dried simulated samples containing 4
bacterial strains of CF origin were distributed to each
participating laboratory (for each strain cell densities of
1.0×108/ml were intended). All strains were selected due to
their definite biochemical differentiation profile by conven-
tional and biochemical tests (API systems, BioMerieux). Each
simulated specimen contained one strain of S. aureus, one
strain of Burkholderia multivorans (API 20NE-code:
5067577/B. cepacia complex after 48 h) and twoP. aeruginosa
variants, one mucoid (termed P. aeruginosa 1, API 20NE-
code: 1354575/P. aeruginosa after 48 h) and one non-mucoid
of smaller colony size (termed P. aeruginosa 2, API 20NE-
code: 1140575/P. aeruginosa after 48 h). P. aeruginosa 1
exhibited a mucoid, brown pigmented phenotype with
susceptibility to all anti-pseudomonal antibiotics asked for,
except ciprofloxacin, whereasP. aeruginosa 2 was selected for
its non-mucoid, non-pigmented and MDR phenotype.
In August 2004, the test samples together with the
questionnaires were sent within 12 h to 18 CF laboratories
distributed all over Germany. The laboratories were instructed
to add 500 μl trypticase soy broth, mix gently, incubate 15min
at 37 °C, direct samples to routine diagnostic procedures and
report on potential pathogens within 3 weeks. Pre-treatment
(e.g., with dithiothreitol) was not recommended. To test the
stability of simulated samples during postal transport, speci-
menswere stored at room temperature (RT) for 12 h and then at
4 °C and were investigated in triplicate at day 1 to day 7 by
CLSth and CLNth, respectively. All four CF strains were
reproducibly detected from each sample with individual
colony forming units (CFU) of about 1.9×108±2.8 for
P. aeruginosa 1, 2.9×107 ±3.1 for P. aeruginosa 2,
3.2 × 108 ± 1.2 for S. aureus and 1.3 × 108 ± 1.2 for
B. multivorans. Antimicrobial susceptibility testing of the CF
isolates was performed in triplicate by CLSth and CLNth.
Minimal inhibitory concentrations (MICs) were determined
Table 2
Identification methods/systems used by participants
Identification system No. of laboratories
S. aureus
Conventional biochemical tests 9
Api ID32Staph (BioMerieux) 3
Vitek (BioMerieux) 3
BDPhoenix (Becton Dickinson) 2
Micronaut system (Merlin) 1
16S rDNA sequencing 1
B. multivorans
Conventional biochemical tests 2
GLC-FAMEa 1
Api 20NE (BioMerieux) 10
ATB 32 GN (BioMerieux) 1
BBL crystal enteric (Becton Dickinson) 1
Vitek (BioMerieux) 1
BDPhoenix (Becton Dickinson) 2
Micronaut system (Merlin) 1
16S rDNA sequencing 3
recA sequencing 2
P. aeruginosa 1
Conventional biochemical tests 3
GLC-FAMEa 1
Api 20NE (BioMerieux) 6
ID 32GN (BioMerieux) 1
BBL crystal enteric (Becton Dickinson) 1
Vitek (BioMerieux) 2
BD Phoenix (Becton Dickinson) 2
Micronaut system (Merlin) 1
16S rDNA sequencing 1
P. aeruginosa 2 b
Api 20 NE (Bio Merieux) 2
BD Phoenix (Becton Dickinson) 1
a Gas–liquid chromatography analysis of bacterial fatty acid methyl
esters.
b
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laboratory standards institute) recommendations by CLSth
[22] and microdilution method (Micronaut system, Merlin) by
CLNth.MICs were interpreted as susceptible (S), intermediate
(I) or resistant (R) according to CLSI breakpoints [23].
2.2. Report forms and questionnaires
A report form was provided for each of the four CF test
strains included in the samples. Herein, 12 antimicrobial
agents were listed and the participants were asked to report
these agents and any other antibiotic agent they routinely test
by using their standard AST procedures. Due to the estimated
broad spectrum of AST methodologies, the microbiological
laboratories were asked to score their AST results primarily as
susceptible, intermediate and resistant but to append MIC
values if available. The supplied questionnaire covered
details of cultivation (e.g., media, cultivation temperature
and time), species identification and AST procedures.
3. Results
Clinicalmicrobiology laboratory results and protocols were
provided by 17 of the 18 participating CF laboratories.
Cultivation media, methods for species identification and AST
of the laboratories and microbiological results of simulated CF
specimens are summarized in Tables 1–4, respectively.
3.1. Laboratory results of bacterial cultivation and species
identification
S. aureus and P. aeruginosa 1 were cultivated and
correctly identified by all 17 reporting laboratories. B.
multivorans was identified as a member of the B. cepaciaTable 1
Primary isolation media used by participants for cultivation of distributed
specimens
Culture media No. of laboratories
Liquid culture media 11
Solid media:
Blood agar 17
Chocolate agar 17
Selective media for
Gram-negative bacteria a 17
B. cepacia complex b 12
P. aeruginosa c 3
S. aureus d 8
Fungi e 17
Meropenem agar 1
a MacConckey agar, cystine lactose-electrolyte-deficient agar, Winkle
agar, Endoagar or not specified.
b MAST selective agar, Burkholderia cepacia selective agar, or not
specified.
c Cetrimid or not specified.
d Mannitol salt agar, Columbia colistin-nalidixic acid agar, Chapman agar
or not specified.
e Chromagar, Sabouraud agar, sulfite-polymyxin-sulfadiazine agar,
erythritol-chloramphenicol agar, or not specified.
P. aeruginosa 2 was correctly identified only by 3 laboratories.complex by all 17 laboratories and further specified as
B. multivorans by two laboratories (one of them using recA
sequencing and the other using 16S rDNA sequencing) but
was misidentified as Burkholderia cenocepacia by the third
laboratory based on recA sequencing. P. aeruginosa 2 was
detected only by four of 17 laboratories (23.5%) and correctlyTable 3
Antimicrobial susceptibility testing methods used by participating
laboratories a
Susceptibility testing methods No. of laboratories
Agar dilution method 2
Disc diffusion method 11
E-test method 2
Vitek (BioMerieux) 8
BD Phoenix (Becton Dickinson) 2
Micronaut system (Merlin) 3
Interpretation guidelines b
DIN 8
CLSI 8
a Ten laboratories used two different test methods.
b One laboratory did not report on interpretation guidelines.
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API 20NE System (BioMerieux) or the BD Phoenix
automated system (Becton Dickinson). The fourth laboratory
misidentified P. aeruginosa 2 as Ralstonia picketti using API
20NE System (Code: 1040535), possibly by reading the API
20NE code only once after 24 h of incubation. Thus, 13
laboratories did not detect P. aeruginosa 2. Misidentification
of B. multivorans as B. cenocepacia and overlooking of
P. aeruginosa 2withMDRphenotypemight have great impact
on the clinical treatment and outcome of a CF patient.Table 4
Consiliary laboratories and participants antimicrobial susceptibility testing results
MICs/categories designated by
CLNth CLSth
Microdilution Agar dilutio
S. aureus
Ciprofloxacin 0.5/S b 0.5/S
Tobramycin 1.0/S 0.5/S
Meropenem b 0.125/S b 1.0/S
Fosfomycin – e/S 16.0/S
Gentamicin 0.5/S – e/S
Cotrimoxazole b 8.0/S – e/S
Erythromycin N 8.0/R – e/R
Amoxicillin/clavulanic acid 1.0/S – e/S
Oxacillin 1.0/S – e/S
B. multivorans
Ciprofloxacin 1.0/S 2.0/I
Colistin – e/R N 16.0/R
Ceftazidime 2.0/S 2.0/S
Tobramycin 32.0/R N8.0/R
Meropenem 2.0/S 2.0/S
Fosfomycin –d N 256.0/R
Gentamicin N 32.0/R – e/R
Cotrimoxazole 16.0/S – e/S
P. aeruginosa 1
Ciprofloxacin 4.0/R 2.0/I
Colistin – e/S 2.0/S
Ceftazidime 1.0/S b 1.0/S
Tobramycin 1.0/S 1.0/S
Meropenem 0.25/S b 1.0/S
Fosfomycin –d 128.0/R
Gentamicin 4.0/I – e/I
P. aeruginosa 2 c
Ciprofloxacin 1.0/S b 0.5/S
Colistin – e/S 2.0/S
Ceftazidime 8.0/I N 32.0/R
Tobramycin 4.0/I 4.0/I
Meropenem 8.0/I 32.0/R
Fosfomycin – d 128.0/R
Gentamicin 32.0/R – e/R
a Abbreviations: S, sensitive; I, intermediate; R, resistant; CLNth, German co
laboratory for CF bacteriology south.
b Several substances were not tested by all laboratories.
c P. aeruginosa 2 was detected only by 4 laboratories.
d Substance was not tested by this laboratory.
e MIC values were not determined.3.2. Laboratory cultivation protocols
All 17 laboratories prepared cultivation media by
streaking reconstituted freeze-dried samples using loop
inoculation, while two laboratories in addition plated serial
dilutions of the reconstituted samples and reported on CFU/
ml of individual pathogens. Five of 17 laboratories did not
use B. cepacia complex selective media and nine of 17
laboratories did not use selective media for the detection of
S. aureus. One laboratory used a meropenem containinga
No. of laboratories reporting
strains b
% of labs
correct
n S I R
16 0 0 100
13 0 0 100
13 0 0 100
6 1 3 60.0
16 0 0 100
16 0 0 100
2 0 12 85.7
14 2 0 87.5
17 0 0 100
10 5 2 88.2
0 0 14 100
17 0 0 100
0 1 16 94.0
11 2 3 68.8
0 0 7 100
0 0 15 100
15 2 0 88.2
1 4 12 94.1
14 1 0 93.3
17 0 0 100
12 4 0 75.0
16 0 0 100
2 0 2 50.0
3 10 4 58.8
3 0 1 75.0
3 0 0 100
1 2 1 75.0
0 3 1 75.0
1 1 2 75.0
0 0 0
0 0 4 100
nsiliary laboratory for CF bacteriology north; CLSth, German consiliary
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conditions (duration and temperature) of the primary plates
varied distinctly from 48 h to 7 d and 35 °C to 37 °C,
respectively. Three laboratories did not report on incubation
temperature. Two laboratories reported incubation of B.
cepacia complex selective media at 22 °C and 30 °C,
respectively. Six laboratories used prolonged incubation for
B. cepacia complex selective media and/or fungal selective
media up to 7 days at RT.
All four laboratories successfully cultivating P. aerugi-
nosa 2 used loop inoculation for preparation of cultivation
media and 48 h incubation, two at 36 °C and one of them at
35 °C, while one laboratory did not report on the incubation
temperature. Surprisingly, the two laboratories using serial
dilutions, suggesting improved recovery of different species
and morphotypes from CF samples, and the single laboratory
using Meropenem agar for selection of MDR phenotypes
also missed P. aeruginosa 2.
3.3. Antimicrobial susceptibility testing
AST methods applied by participating laboratories and
reported category results (S/I/R) are shown in Tables 3 and 4.
Percentages of correct results were calculated based on AST
data of CLSth and CLNth. Differences in category results of
CLSth and CLNth occurred only for B. multivorans and
P. aeruginosa 1, both for ciprofloxacin and P. aeruginosa 2
for ceftazidime and meropenem, most likely since
corresponding MIC values clustered near the AST break-
points (Table 4). In such cases, both results were accepted as
correct. The evaluation of the questionnaires revealed that
eight laboratories performed AST according to the standard
of the German Institute for Standardization (DIN) and eight
laboratories according to American CLSI guidelines. One
laboratory did not report on the used AST guidelines.
Although reported only by some laboratories, testing of
fosfomycin caused several errors when S. aureus and
P. aeruginosa 1 were tested, not surprisingly, since the disc
diffusionmethod that was used by themajority of laboratories
is often inaccurate and to date neither approved CLSI nor
DIN breakpoints for fosfomycin are available [23–25].
Furthermore, errors in category results occurred most
frequently for meropenem when B. multivorans was tested
(only 68.8% correct results) and for gentamicin when P.
aeruginosa 1 was tested (58.8% correct results). Among
laboratories reporting categorical errors for meropenem and
gentamicin, two laboratories used the Micronaut automated
system (Merlin), two laboratories used Vitek automated
system (BioMerieux), one laboratory used BD Phoenix
automated system (Becton Dickinson), one laboratory used
the E-Test (Viva Diagnostics) and three laboratories used the
agar diffusion method. One laboratory did not report on its
AST method. Three laboratories all of them using the
Micronaut system, reported major errors (a susceptible
substance was reported resistant) for meropenem when
B. multivorans was tested, although tested MIC values werewithin the susceptible range. The Micronaut system expert
software categorically assesses B. cepacia complex isolates
as meropenem resistant. Thus, evaluation of the question-
naires revealed that discrepancies in AST occurred most
frequently when automated systems (Merlin, Vitek, BD
Phoenix) or the agar diffusion method were used.
4. Discussion
Accurate identification and AST of CF pathogens is
critical to ensure appropriate treatment and infection control
in CF patients. The present study provides a first status on
microbiological practices for CF specimens in German
microbiological laboratories. All laboratories participating in
this EQA trial are experienced in CF microbiology and
associated to centres following at least 100 CF patients.
However, only three from 17 laboratories (18%) reported
fully correct results concerning the cultivation and identifi-
cation of a set of four typical CF pathogens from simulated
clinical specimens. All laboratories isolated and identified
three of the four test strains, namely S. aureus, P. aeruginosa
1 and B. cepacia complex correctly, while P. aeruginosa 2
with an MDR phenotype was problematic for the majority of
participants. Only four laboratories correctly reported the
presence of this strain, but one misidentified it as R. pickettii.
Three laboratories determined the genomic species of the
B. cepacia complex test strain, two of them correctly as
B. multivorans, but one laboratory misidentified it as
B. cenocepacia. This reporting error may have fatal impli-
cations on the patient's clinical therapy strategies and
prognosis, as B. cenocepacia infection is associated with a
worse outcome, especially following lung transplantation,
than those with B. multivorans [26]. Likewise, overlooking
of P. aeruginosa 2 could result in the selection of an in-
effective antibiotic treatment.
The evaluation of the questionnaires revealed a broad
heterogeneity between microbiological protocols regarding
cultivation and AST procedures. Cultivation procedures
implemented for non-CF specimens may fail to detect
fastidious species found in CF specimens like B. cepacia
complex, slow growing mucoid P. aeruginosa or small
colony variants (SCV) that can easily be overgrown by other
micro-organisms. Failure in the recovery of these CF
pathogens may negatively influence clinical treatment, as
probably important etiologic pathogens or more resistant
components of the infection will be missed. Further, the
omission or the delayed separation of infected patients may
lead to an increased risk of patient-to-patient transmission.
For the primary processing of CF respiratory specimens
the use of selective media and prolonged incubation periods
are essential. For the optimal recovery of gram-negative
bacteria, mainly P. aeruginosa, selective media such as
Pseudomonas isolation, cetrimide, MacConkey or acetamide
agar are required. To improve the recovery of H. influenzae,
chocolate agar supplemented with vancomycin and/or
bacitracin and clindamycin is recommended [15]. Due to
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and their association with a poor prognosis, the use of
isolation media with enhanced recovery rate for this
organism are strictly recommended (e.g., MAST selective
agar, B. cepacia selective agar, Pseudomonas cepacia agar,
oxidation-fermentation polymyxin bacitracin lactose agar,
Stewart's composite arginine medium) [16–19]. To ensure
the reliable recovery of S. aureus, mannitol salt agar or other
media have been used (e.g., Columbia colistin-nalidixic
acid agar, lipase-salt-mannitol agar). For the recovery of
S. aureus, SCVs chromogenic agar media were shown to be
reliable (e.g., S. aureus ID agar, CHROMagar Staph aureus)
[27]. Detection of MDR variants is facilitated by agar media
supplemented with antibiotics, like meropenem, tobramycin
or colistin [28–31].
As a consequence, in CF selective media have been
advocated by American authorities for the optimum recovery
of H. influenzae, S. aureus, P. aeruginosa and B. cepacia
complex [19]. Surprisingly, only eight of 17 laboratories
used selective media for S. aureus and 12 of 17 laboratories
for B. cepacia complex. Although the high bacterial load of
S. aureus and B. multivorans most likely enabled all
laboratories to detect both strains without usage of specific
selective media, these pathogens could be missed when
lower CFU are present and/or more rapidly growing species
(e.g., P. aeruginosa) obscure their detection [32]. Likewise,
the overlooking of P. aeruginosa 2 appear to be the result of
the more prominent colony size and/or slightly higher cell
count of P. aeruginosa 1, S. aureus and B. multivorans.
While almost all participating laboratories prepared bacterial
cultures only by loop-inoculation of undiluted samples,
quantitative cultures performed by CLSth and CLNth
demonstrated that P. aeruginosa 2 was present in easily
detectable amounts. This underlines the need of adequate
sample homogenization and whole plate inoculation of serial
dilutions to efficiently separate different CF pathogens and
phenotypic variants from the more challenging viscous CF
airway secretions that in contrast to the homogeneous freeze-
dried sample contain heterogeneously distributed bacteria in
biofilm-like microcolonies.
For species identification, the majority of laboratories
used biochemical methods while three laboratories confirmed
B. cepacia complex identification by 16S rDNA sequencing.
Several studies have shown that conventional biochemical
tests can misidentify B. cepacia complex species, biochem-
ical inactive and newly emerging CF pathogens [6,33]. Thus,
laboratories processing CF specimens need access to
molecular identification tools and/or in equivocal cases the
possibility to send specimens and/or isolates to national or
international referral laboratories on CF microbiology [34].
Services regarding the genomic species identification of
B. cepacia complex isolates are available by the European
B. cepacia complex Referral Laboratory and Repository
(information via http://go.to/cepacia).
Moreover, accurate AST in particular of highly resistant
CF isolates plays a critical role in the diagnostic microbi-ology [35]. The evaluation of the questionnaires revealed
that most laboratories used either automated commercial
systems (13 of 17 laboratories) and/or the disc diffusion
method (11 of 17 laboratories), whereas either CLSI or DIN
guidelines were used. Most categorical errors occurred when
automated systems were applied followed by the agar
diffusion test. The overall strain-specific error rates for
AST results were found to be as follows: P. aeruginosa 2
B. multivorans P. aeruginosa 1NS. aureus (excluding
fosfomycin due to the absence of clear AST guidelines for
this agent). Categorical errors occurred mostly when MIC
values of the test strains clustered near the corresponding
breakpoints. Very major errors (a resistant substance was
reported susceptible) that may lead to an ineffective
antibiotic treatment occurred only for P. aeruginosa 1
when fosfomycin was tested and surprisingly, twice for
S. aureus when erythromycin was tested. The highest num-
ber of major errors occurred for B. multivorans when
meropenem was tested, probably due to an algorithm of the
Micronaut expert software (Merlin) that generally scores
B. cepacia isolates as meropenem resistant.
In general, instead of the labor-intense agar dilution
method mainly the broth microdilution method and the agar-
bond disk diffusion test have been considered to be
appropriate for the AST of CF strains [36,37]. Nevertheless,
the disc diffusion testing of fastidious CF isolates, especially
for mucoid P. aeruginosa, may be inaccurate [36]. The use
of automated commercial systems (Vitek and MicroScan-
WalkAway) for testing CF pathogens was shown to be
inaccurate and thus has not been recommended by American
authorities [38]. The wide use of automated systems among
participants may account for a high number of reported AST
errors. However, up-to-date studies evaluating newer gen-
erations of automated systems in the field of CF microbi-
ology are not available. The Merlin Micronaut system was
shown to be reliable for P. aeruginosa CF isolates [39,40]. In
2005 revised CLSI guidelines have been released that for the
first time include an approval of the disc diffusion for the
testing of B. cepacia complex and S. maltophilia when
prolonged incubation times and adapted breakpoints are
used. Nevertheless, the most suitable AST method of isolates
obtained from CF patients is increasingly under debate.
Beyond methodological discrepancies the poor correlation of
in vitro data and the outcome of the patients is disappointing,
irrespective of the testing of single antibiotics or antibiotic
combinations [41–43]. This seems to be not surprisingly,
since (i) the definition of resistance deduced from in vitro
testing of bacteria and discrete clinical breakpoints is
directed in particular towards the treatment of acute
infections and does not equally fit to the situation of chronic
infections, (ii) in CF only a few possibly representative
isolates were tested and (iii) rather all in vitro methods are
inappropriate to mimic the complex environment of the CF
lung comprising various sputum components, high bacterial
densities, biofilm growth, oxygen restriction and the
coexistence of different species or phenotypic variants [44].
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more rational basis for prescribing antibiotics for CF lung
infection are missing, reliable conventional AST data should
not be rejected since they may be still essential to guide
antibiotic therapies during early CF disease and exacerba-
tions and to unmask multiresistant isolates with respect to
epidemiological and hygienic purposes [45,46].
In conclusion, this study highlighted that national EQA
schemes are important to assess and improve the microbio-
logical performance of CF respiratory tract specimens. As a
part of this project, recommendations for German clinical
microbiology laboratories processing CF respiratory secre-
tions were recently published [21]. Probably yearly con-
ducted EQA schemes are desirable to periodically evaluate
the compliance of microbiological laboratories to guidelines
that should be regularly updated, e.g., with respect to changes
in the epidemiology of CF lung infection.
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